Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women
Marksans Pharma Limited announced that its wholly owned subsidiary in the United Kingdom, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its product Exemestane 25mg film-coated tablets.
Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women. This approval strengthens Marksans Pharma’s oncology portfolio and reinforces its commitment to expanding its presence in the regulated markets with high-quality, affordable medicines.
Commenting on the approval, Mark Saldanha, Managing Director of Marksans Pharma Limited, said, “This authorization from the UK MHRA marks another important milestone in our growth journey. It reflects our continued focus on developing and delivering high-quality pharmaceutical products to meet critical patient needs across global markets.”
With this approval, Relonchem Limited continues to enhance its product offerings in the UK, further solidifying Marksans Pharma’s position as a trusted global healthcare provider.